Drew is a co-founder and joined RCG in November of 2023 as a board member and President. He specializes in Strategy, Portfolio Management and Competitive Insights by having a unique breadth of knowledge spanning science, manufacturing, and strategic marketing. He provides insightful market intelligence, product evaluations, and strategic recommendations based on past experiences in consulting and corporate portfolio management.
Prior to RCG Drew was at Molekule Consulting where he progressed from an Engagement manager to COO. He was responsible for the end to end 15-25 client engagements per year across multiple therapeutic areas.
Drew started his career as a research chemist supporting legacy manufacturing and new product development at Covidien, Pfizer, and the US FDA. After completing his M.B.A Drew transitioned to Strategic Marketing where he was responsible for pipeline product sections, product launches and evaluation of BD&L opportunities.
SUBJECT MATTER EXPERTISE & THERAPY AREA
Market Access
Competitive Simulation Workshops “War Games”
Biosimilars and Generics
Manufacturing & Supply Chain Intelligence
Portfolio Management / Product Selection /LCM Strategy
Strategic Planning Cycle Project Management Business
Development and Licensing Forecasting and Modeling
Device Combination products
Immunology & Inflammation
Ophthalmology
CNS
Oncology
Veritux independent consultants are available where you need them – in all major markets and every global region.
